Literature DB >> 7997434

Proliferation-dependent vs. independent programmed cell death of prostatic cancer cells involves distinct gene regulation.

Y Furuya1, J T Isaacs.   

Abstract

Androgen-independent Dunning R-3327 AT-3 rat prostatic cancer cells can be induced to undergo programmed cell death in either a proliferation-dependent or independent manner depending upon the therapeutic agent used. In the present study, 5-fluorodeoxyuridine (5-FrdU) was used to induce proliferation-dependent death of the AT-3 cells via its ability to inhibit thymidylate synthetase. Ionomycin and thapsigargin were used to induce proliferation-independent death of these cells via their ability to sustain an elevation in intracellular free Ca2+. Based upon the temporal sequence of DNA fragmentation, morphologic changes, and loss of cell viability, each of the three test agents, at the doses used, induces the programmed death of AT-3 cells with essentially identical kinetics. Based upon these similarities, comparisons of the pattern of gene expression during the proliferation-dependent (i.e., 5-FrdU-induced) vs. proliferation-independent (i.e., ionomycin and thapsigargin-induced) programmed death of AT-3 cells allow identification of genes whose enhanced expression is involved in the initiation vs. completion of programmed cell death. Based upon this approach, enhanced H-ras and TRPM-2 expression is associated with initiation of proliferation-dependent programmed death of AT-3 cells while enhanced c-myc, calmodulin, and alpha-prothymosin expression is associated with initiation of proliferation-independent programmed death of these cells. In contrast, enhanced expression of glucose-regulated 78 kilodalton and tissue transglutaminase genes are associated with the completion of programmed cell death, since their expression is enhanced in both proliferation-dependent and independent programmed cell death of AT-3 cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7997434     DOI: 10.1002/pros.2990250604

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  8 in total

Review 1.  Transglutaminase induction by various cell death and apoptosis pathways.

Authors:  L Fesus; A Madi; Z Balajthy; Z Nemes; Z Szondy
Journal:  Experientia       Date:  1996-10-31

2.  Bcl-2, tissue transglutaminase and p53 protein expression in the apoptotic cascade in ribs of premature infants.

Authors:  H Y Stevens; J Reeve; B S Noble
Journal:  J Anat       Date:  2000-02       Impact factor: 2.610

3.  Dr. Coffey's visionary contributions to urological research in China and Japan.

Authors:  Jun Shimazaki; Leland Wk Chung; Haiyen E Zhau; Tomohiko Ichikawa
Journal:  Am J Clin Exp Urol       Date:  2018-04-01

4.  Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen.

Authors:  S R Denmeade; W Lou; J Lövgren; J Malm; H Lilja; J T Isaacs
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

Review 5.  Natural products as modulators of eukaryotic protein secretion.

Authors:  Hendrik Luesch; Ville O Paavilainen
Journal:  Nat Prod Rep       Date:  2020-02-18       Impact factor: 13.423

6.  Physical and functional interaction of androgen receptor with calmodulin in prostate cancer cells.

Authors:  Eugenia Cifuentes; Jennifer M Mataraza; Barbara A Yoshida; Mani Menon; David B Sacks; Evelyn R Barrack; G Prem-Veer Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-26       Impact factor: 11.205

7.  Induction of programmed death/apoptosis androgen-dependent mouse mammary tumor cell line (Shionogi Carcinoma 115) by androgen withdrawal.

Authors:  Y Furuya; J T Isaacs; J Shimazaki
Journal:  Jpn J Cancer Res       Date:  1995-12

Review 8.  Mipsagargin: The Beginning-Not the End-of Thapsigargin Prodrug-Based Cancer Therapeutics.

Authors:  John T Isaacs; William Nathaniel Brennen; Søren Brøgger Christensen; Samuel R Denmeade
Journal:  Molecules       Date:  2021-12-09       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.